Dabrafenib Mesylate

iStock, Diki Prayogo Executives at Novartis have not been shy about a desire to buy more companies, with cardiovascular a big focus. In total, the Swiss pharma has put $17.23 billion on the line in M&A and licensing deals this year. Novartis’ business development team sure has been busy. The Swiss pharma has notched three deals this month alone, including Tuesday’s $1.4 billion acquisition of cardiovascular biotech Tourmaline Bio. Earlier in the month, Novartis revealed two licensing deals, with Argo Biopharmaceutical and Arrowhead Pharma, worth a combined $7.56 billion in total potential deal value. In total this year, Novartis has put $17.23 billion on the line in M&A and licensing deals. The Tourmaline transaction will give Novartis access to an IL-6 targeting program for atherosclerotic cardiovascular disease (ASCVD) with the monocloncal antibody pacibekitug. BMO Capital Markets Tuesday morning said that Novartis offered a 37% premium in transaction value for the therapy, reflecting its best-in-class profile. The drug will compete with Novo Nordisk’s Phase III therapy ziltivekimab, which was acquired via Corvidia Therapeutics for $725 million in 2020. Novartis has been eager to fill up its pipeline, as the chronic heart failure medicine Entresto is expected to lose its patent exclusivity this year. Novartis will also contend with generic competition for Xolair this year and Jakafi next. Cosentyx and Tafinlar will also fall out of patent protection before the end of 2030. During a second-quarter earnings call in July, CFO Harry Kirsch said that Novartis is looking for “value-creating bolt-on deals.” The business development team—headed by Chief Strategy Growth Officer Ronny Gal—has signed 30 deals over the past two years, Kirsch noted. Kirsch specifically named the Regulus Therapeutics transaction from April as an example of the type of deal Novartis will be looking for going forward. That deal totaled $1.7 billion and bolstered Novartis’ oligonucleotide portfolio with the addition of autosomal dominant polycystic kidney disease (ADPKD) therapy farabursen. In late 2024, Novartis executives indicated a desire to have multiple assets in the clinic for arrhythmia by the end of 2025. Asked about this during the earnings call, CEO Vas Narasimhan said the goal remains top of mind. The company signed several licensing deals for preclinical assets to accomplish this—including one with Flagship Pioneering’s ProFound Therapeutics in June. “We see this as an area where we have unique expertise, probably one of the few companies still going after addressing cardiac arrhythmias,” Narasimhan told analysts on the call. “And obviously, if successful, market sizes here are quite large and the opportunity to use a medicine versus using the device-based cardio version is quite compelling for patients.”

前 言        胰腺癌曾被认为是"靶向荒漠"，但近年研究发现，约15%患者携带有临床意义的可靶向突变！     如果你是晚期胰腺癌患者/家属，或是希望了解最新治疗的行业人士，这篇"靶向作战地图"请收藏！ KRAS突变：从"不可成药"到突破口 1. KRAS突变现状（占胰腺癌90%！） 🔬 主要亚型： - G12D（~40%）：尚无获批靶向药（但疫苗/新药在研） - G12V（~30%）：临床试验聚焦中 - G12C（~1-2%）：已有多癌种药物sotorasib（AMG510） 💉 关键数据： - CodeBreaK 100试验：KRAS G12C胰腺癌患者，sotorasib客观缓解率21% - 局限：胰腺癌中疗效弱于肺癌（可能因肿瘤微环境差异） 📢 重要提醒： ① KRAS G12C突变需NGS检测确认 ② 目前仅二线后考虑使用，推荐联合MEK抑制剂（如曲美替尼） 罕见但可靶向的"钻石突变"     这些罕见突变/融合有专属药物！ 1️⃣ 突变类型：NTRK融合 对应药物：拉罗替尼/恩曲替尼 响应率：>75%肿瘤缩小   检测方法：RNA-based NGS 2️⃣ 突变类型：BRAF V600E 对应药物：达拉非尼+曲美替尼 响应率：33%客观缓解 检测方法：PCR/NGS  3️⃣ 突变类型： HER2扩增 对应药物：曲妥珠单抗+化疗    响应率：病例报告有效  检测方法：FISH/NGS     关键行动指南：如何抓住靶向机会？ 什么时候要做NGS检测？ ✅ 初诊晚期时：寻找一线靶向机会 ✅ 标准治疗失败后：挖掘二线选择 ✅ 有家族癌症史：筛查遗传易感突变 如何匹配药物/临床试验？ 🔍 权威数据库推荐： - ClinicalTrials.gov（搜索"胰腺癌+突变类型"） - NCCN胰腺癌指南（每年更新靶向推荐） - 公益组织"癌度"（提供临床试验匹配服务）  寻找新希望：如何挑选临床试验？     临床试验是接触未来最新疗法（如新型免疫治疗、靶向药、细胞治疗等）的有效途径。即使没有常见突变靶点，也可能有针对其他机制的新药试验。 1、如何寻找合适的临床试验？ ✅咨询主治医生：他们最了解你的病情和当地资源。 ✅权威数据库查询： 1️⃣国家药品监督管理局药物临床试验登记与信息公示平台（http://www.chinadrugtrials.org.cn） 2️⃣美国ClinicalTrials.gov（https://clinicaltrials.gov） 3️⃣医院官网、微信公众号等 2、如何进行评估？ ✅看阶段：I期试验重在安全性，II/III期试验更看重有效性。 ✅看设计：是否设有“对照组”（使用标准方案）？如果试验组是“试验药+标准化疗” vs 对照组“安慰剂+标准化疗”，通常风险较低。 ✅看入排标准：根据您的病情阶段、过往治疗史和身体情况等判断是否符合试验入组标准。 ✅看实际问题：试验中心在哪？需要频繁往返吗？检查治疗费用是免费还是部分报销？这些问题必须提前问清楚。 🎯 给不同读者的专属建议 ▸ 患者/家属：保存病理白片，找三甲医院做500+基因panel检测 ▸ 临床医生：对PDAC患者常规检测KRAS亚型+NTRK/BRAF/HER2 ▸ 行业人士：关注KRAS多抑制剂联用（如G12D+MEK抑制剂）试验     "哪怕只有1%的突变概率，也值得100%的检测努力！" 💡 关注Biotech视野 了解自己，关爱家人，健康并非遥不可及~